Arvinas, Inc. (ARVN)
ARVN Stock Price Chart
Explore Arvinas, Inc. interactive price chart. Choose custom timeframes to analyze ARVN price movements and trends.
ARVN Company Profile
Discover essential business fundamentals and corporate details for Arvinas, Inc. (ARVN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 Sept 2018
Employees
430.00
Website
https://www.arvinas.comCEO
John G. Houston
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
ARVN Financial Timeline
Browse a chronological timeline of Arvinas, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 9 Feb 2026
Upcoming earnings on 29 Oct 2025
EPS estimate is -$0.83, while revenue estimate is $28.89M.
Earnings released on 6 Aug 2025
EPS came in at -$0.84 surpassing the estimated -$0.87 by +3.45%, while revenue for the quarter reached $22.40M , missing expectations by -10.40%.
Earnings released on 1 May 2025
EPS came in at $1.14 surpassing the estimated -$0.86 by +232.56%, while revenue for the quarter reached $188.80M , beating expectations by +346.28%.
Earnings released on 11 Feb 2025
EPS came in at -$0.63 surpassing the estimated -$1.07 by +41.12%, while revenue for the quarter reached $59.20M , beating expectations by +39.19%.
Earnings released on 30 Oct 2024
EPS came in at -$0.68 surpassing the estimated -$0.88 by +22.73%, while revenue for the quarter reached $102.40M , beating expectations by +72.14%.
Earnings released on 30 Jul 2024
EPS came in at -$0.49 surpassing the estimated -$0.72 by +31.94%, while revenue for the quarter reached $76.50M , beating expectations by +40.26%.
Earnings released on 7 May 2024
EPS came in at -$0.97 surpassing the estimated -$1.48 by +34.46%, while revenue for the quarter reached $25.30M , missing expectations by -27.38%.
Earnings released on 27 Feb 2024
EPS came in at -$2.53 falling short of the estimated -$1.33 by -90.23%, while revenue for the quarter reached -$43.10M , missing expectations by -187.42%.
Earnings released on 7 Nov 2023
EPS came in at -$1.18 surpassing the estimated -$1.52 by +22.37%, while revenue for the quarter reached $34.60M , missing expectations by -14.59%.
Earnings released on 8 Aug 2023
EPS came in at -$1.25 surpassing the estimated -$1.67 by +25.15%, while revenue for the quarter reached $54.50M , beating expectations by +85.37%.
Earnings released on 5 May 2023
EPS came in at -$1.54 falling short of the estimated -$1.46 by -5.48%, while revenue for the quarter reached $32.50M , beating expectations by +17.29%.
Earnings released on 23 Feb 2023
EPS came in at -$1.56 falling short of the estimated -$1.04 by -50.00%, while revenue for the quarter reached $38.00M , beating expectations by +6.39%.
Earnings released on 8 Nov 2022
EPS came in at -$1.24 falling short of the estimated -$0.98 by -26.53%, while revenue for the quarter reached $30.30M , missing expectations by -12.68%.
Earnings released on 4 Aug 2022
EPS came in at -$1.32 falling short of the estimated -$1.02 by -29.41%, while revenue for the quarter reached $31.30M , beating expectations by +26.46%.
Earnings released on 5 May 2022
EPS came in at -$1.20 falling short of the estimated -$0.85 by -41.18%, while revenue for the quarter reached $24.20M , missing expectations by -4.93%.
Earnings released on 28 Feb 2022
EPS came in at -$1.00 falling short of the estimated -$0.78 by -28.21%, while revenue for the quarter reached $26.30M , beating expectations by +86.02%.
Earnings released on 3 Nov 2021
EPS came in at -$0.94 falling short of the estimated $2.85 by -132.98%, while revenue for the quarter reached $9.28M , missing expectations by -96.22%.
Earnings released on 5 Aug 2021
EPS came in at -$1.03 falling short of the estimated -$0.84 by -22.62%, while revenue for the quarter reached $5.54M , beating expectations by +0.01%.
Earnings released on 4 May 2021
EPS came in at -$0.84 falling short of the estimated -$0.78 by -7.69%, while revenue for the quarter reached $5.54M , missing expectations by -19.84%.
Earnings released on 1 Mar 2021
EPS came in at -$0.99 falling short of the estimated -$0.78 by -26.92%, while revenue for the quarter reached $2.22M .
Earnings released on 5 Nov 2020
EPS came in at -$0.79 falling short of the estimated -$0.67 by -17.91%, while revenue for the quarter reached $7.60M , beating expectations by +16.18%.
ARVN Stock Performance
Access detailed ARVN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.